Juniper Pharmaceuticals Inc logo

JNP - Juniper Pharmaceuticals Inc News Story

$11.5 0.0  0.0%

Last Trade - 13/08/18

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £40.0m
Position in Universe th / 6849

BRIEF-Juniper Pharmaceuticals announces strategic reprioritization

Mon 18th September, 2017 9:05pm
Sept 18 (Reuters) - Juniper Pharmaceuticals Inc  JNP.O  
    * Juniper Pharmaceuticals announces strategic 
reprioritization 
    * Juniper Pharmaceuticals Inc - Company will begin to focus 
its research and development organization on JNP-0201 for 
hormone replacement therapy 
    * Juniper - Actions are expected to result in cost savings 
that will position Juniper to achieve at least a cash flow 
neutral position for 2018 
    * Juniper Pharmaceuticals Inc - As a result of focused 
research and development strategy, company will implement an 
approximately 8% headcount reduction 
    * Juniper Pharmaceuticals Inc - Company also expects to 
reduce its overall new product research and development spend in 
connection with its revised focus 
    * Juniper Pharmaceuticals Inc - Bridget Martell, M.D., chief 
medical officer, will be stepping down from company effective 
today, September 18, 2017 
    * Juniper Pharmaceuticals - Headcount reduction will result 
in estimated annual savings in personnel-related costs of about 
$1.9 million beginning in 2018 
    * Juniper  - Estimates it will incur charges of about $0.6 
million to $0.7 million for one-time severance and other 
employee related costs in Q3 
 
Source text for Eikon:  ID:nPn9b5Nlra  
Further company coverage:  JNP.O  
 
 ((Bangalore.newsroom@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.